273 related articles for article (PubMed ID: 8971023)
1. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy.
Gao GP; Yang Y; Wilson JM
J Virol; 1996 Dec; 70(12):8934-43. PubMed ID: 8971023
[TBL] [Abstract][Full Text] [Related]
2. Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.
Gorziglia MI; Lapcevich C; Roy S; Kang Q; Kadan M; Wu V; Pechan P; Kaleko M
J Virol; 1999 Jul; 73(7):6048-55. PubMed ID: 10364357
[TBL] [Abstract][Full Text] [Related]
3. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
4. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4.
Brough DE; Lizonova A; Hsu C; Kulesa VA; Kovesdi I
J Virol; 1996 Sep; 70(9):6497-501. PubMed ID: 8709289
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
6. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector.
Wang Q; Greenburg G; Bunch D; Farson D; Finer MH
Gene Ther; 1997 May; 4(5):393-400. PubMed ID: 9274715
[TBL] [Abstract][Full Text] [Related]
7. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants.
Krougliak V; Graham FL
Hum Gene Ther; 1995 Dec; 6(12):1575-86. PubMed ID: 8664382
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.
Lusky M; Christ M; Rittner K; Dieterle A; Dreyer D; Mourot B; Schultz H; Stoeckel F; Pavirani A; Mehtali M
J Virol; 1998 Mar; 72(3):2022-32. PubMed ID: 9499056
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products.
Christ M; Louis B; Stoeckel F; Dieterle A; Grave L; Dreyer D; Kintz J; Ali Hadji D; Lusky M; Mehtali M
Hum Gene Ther; 2000 Feb; 11(3):415-27. PubMed ID: 10697116
[TBL] [Abstract][Full Text] [Related]
10. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.
Yeh P; Dedieu JF; Orsini C; Vigne E; Denefle P; Perricaudet M
J Virol; 1996 Jan; 70(1):559-65. PubMed ID: 8523570
[TBL] [Abstract][Full Text] [Related]
11. Improved adenoviral vector for vascular gene therapy : beneficial effects on vascular function and inflammation.
Qian HS; Channon K; Neplioueva V; Wang Q; Finer M; Tsui L; George SE; McArthur J
Circ Res; 2001 May; 88(9):911-7. PubMed ID: 11349000
[TBL] [Abstract][Full Text] [Related]
12. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors.
Armentano D; Zabner J; Sacks C; Sookdeo CC; Smith MP; St George JA; Wadsworth SC; Smith AE; Gregory RJ
J Virol; 1997 Mar; 71(3):2408-16. PubMed ID: 9032378
[TBL] [Abstract][Full Text] [Related]
13. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions.
Wang Q; Jia XC; Finer MH
Gene Ther; 1995 Dec; 2(10):775-83. PubMed ID: 8750018
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human adenovirus 35 and derivation of complex vectors.
McVey D; Zuber M; Ettyreddy D; Reiter CD; Brough DE; Nabel GJ; King CR; Gall JG
Virol J; 2010 Oct; 7():276. PubMed ID: 20959004
[TBL] [Abstract][Full Text] [Related]
15. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo.
Lieber A; He CY; Kirillova I; Kay MA
J Virol; 1996 Dec; 70(12):8944-60. PubMed ID: 8971024
[TBL] [Abstract][Full Text] [Related]
16. Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.
Raper SE; Haskal ZJ; Ye X; Pugh C; Furth EE; Gao GP; Wilson JM
Hum Gene Ther; 1998 Mar; 9(5):671-9. PubMed ID: 9551615
[TBL] [Abstract][Full Text] [Related]
17. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses.
Dedieu JF; Vigne E; Torrent C; Jullien C; Mahfouz I; Caillaud JM; Aubailly N; Orsini C; Guillaume JM; Opolon P; Delaere P; Perricaudet M; Yeh P
J Virol; 1997 Jun; 71(6):4626-37. PubMed ID: 9151856
[TBL] [Abstract][Full Text] [Related]
18. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D; Wildner O
BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
[TBL] [Abstract][Full Text] [Related]
19. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors.
Mizuguchi H; Kay MA
Hum Gene Ther; 1999 Aug; 10(12):2013-7. PubMed ID: 10466635
[TBL] [Abstract][Full Text] [Related]
20. Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3.
Yew NS; Marshall J; Przybylska M; Wysokenski DM; Ziegler RJ; Rafter PW; Li C; Armentano D; Cheng SH
Hum Gene Ther; 1999 Jul; 10(11):1833-43. PubMed ID: 10446923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
